Effect of Azithromycin in treatment of cutaneous leishmaniasis

Dindar S. Qurtas

ABSTRACT

Introduction: Leishmaniasis is a vector born protozoal infection. Cutaneous leishmaniasis outbreak occurred during 2014 in Erbil governorate, Kurdistan-Iraq. First choice of its treatment is pentavalent antimony. Other options of treatment are available. Azithromycin is used as trial to be effective but human studies are lacking.

Patients and Methods: Prospective randomized open labeled interventional study conducted on 63 patients. The sample divided in to two groups. Group A received only intra-lesional sodium stibogluconate and the group B received combination therapy of intra-lesional sodium stibogluconate and azithromycin 500 mg orally. Follow up done for lesions’ healing at 6th week and at the end of 8th week of therapy.

Results: Nodular lesions were dominant morphology among the Lesions (71.5%). Lesions mostly were ulcerated (59%). Mean duration of lesions were 3 ± 1.1 and 2.4 ± 1.8 weeks in patients of group A and B respectively. At 6th week in patients of group A, there were 13(41.9%) patients with complete healing of the lesions, while in group B it was found in 23(71.8%) patients. At the end of 8th week group A patients showed complete healing in 21(67.7%) patients while in patients of group B complete healing found in 27(84.3%).

Conclusions: Results of this study concludes that combination therapy of azithromycin and intra-lesional sodium stibogluconate provides more therapeutic effect if compared with the effect of intra-lesional sodium stibogluconate alone.

Key words: Cutaneous leishmaniasis, intra-lesional sodium stibogluconate, azithromycin

تأثير أزثرومايسين في علاج عدوى ليشمانيا الجلدية (حبة بغداد)

المقدمة: عدوى ليشمانيا هو مرض طفيلي متوطن في الحشرات. شهدت مدينة اربيل -كردستان العراق انتشار وبائي لعدوى ليشمانيا الجلدية (حبة بغداد) في عام 2014. العلاج الأساسي الأولي لهذه العدوى هو- بنتا فالنت انتيموني، خيارات أخرى تعلمت هذه العدوى أيضاً مؤشرة. المضاد الحيوي أزثرومايسين استخدم حديثا كعلاج فعال لعدوى حبة بغداد الجلدية ولكن هذه البحوث تخلو من التجارب البشرية.

خطة البحث: أجريت دراسة بحثية تداخلية مستقلة عشوائية على 36 مريض. تم فرز العينة البحثية إلى مجموعتين المجموعة الأولى -استخدم في علاجها زرق ابر صوديوم ستوكوكوينت بشكل مباشر داخل العدوى الجلدية فقط لا غير. المجموعة الثانية-استخدمت في علاجها كل من زرق ابر صوديوم ستوكوكوينت المباشر بالإضافة إلى استخدام المضاد الحيوي أزثرومايسين كعلاج مقارب وجرعة 500 ملغ حبوب فموية. تم متابعة المسارات العلاجية للعدوى الجلدية خلال الأسبوع السادس وفي نهاية الأسبوع السادس من العلاج.

النتائج:

- تدل في اغلب العدوى الجلدية نسبة 71.5% بينما تصل نسبة الفروخ في هذه العدوى إلى 59%.
- المتوسط القياسي للعلاج يتراوح من 3.3 ± 1.1 أسبوع و 1.8 ± 0.4 أسبوع لكل من المجموعة الأولى والثانية على التوالي.
- في الأسبوع السادس من المجموعة الأولى يصل عدد المرضى الذين تم شفافيهم بشكل كامل من العدوى الجلدية إلى 13 مريض بنسبة 44.9% بينما يصل عدد شفاء المرضى في المجموعة الثانية إلى 23 مريض (نسبة 71.8%).

MBCh., MD, PhD, Hawler Medical University, College of Medicine, Dermatology Unit, Lecturer
في نهاية الأسبوع الثامن وصل عدد المرضى الذين تم شفاؤهم بشكل كامل من العدوى الجلدية إلى 40 مريض (نسبة 67.7٪)، بينما وصلت نسبة الشفاء في المجموعة الثانية إلى 48٪ ما يعادل 27 مريض.

الاستنتاج: النتائج المستنبطة من هذا البحث تدعم اقتران المضاد الحيوي أزثرومايسين مع ابر الصوديوم ستوبكلوكونيت لتعطي فعالية علاجية أكثر مقارنتا مع ابر الصوديوم ستبوكلوكونيت وحدها.

INTRODUCTION

Leishmaniasis is parasitic infection caused by Leishmania species and transmitted to human by sand-fly vector.[1] Cutaneous leishmaniasis (CL) is an endemic infection in Iraq.[2,3] Its outbreak in Erbil governorate happened in 2015.[4] This skin disease is self-limited but its course may prolong for one year or more.[5,6] Also this disease could have negative impact on various aspects of the patients as physical, psychological, social and economic.[7,9] Skin lesions usually appear weeks to months after insect bite as papules, plaques and nodules. These lesion indurate, crusts, ulcerate accordingly.[8] The last healing residua usually is disfiguring scar.[9] Treatment of CL with pentavalent antimony, especially sodium stibogluconate SSG (pentostam) intra-lesionally for non-disseminated cases was successfully used.[10] Other drugs like azoles, rifampicin, metronidazole, paromomycin etc. are used for its treatment, but still SSG remains the first line of the treatment of CL despite its side effects and cost.[11][12] Many studies were conducted to optimize treatment of CL because resistant cases to the above mentioned treatments are going to grow up.[13,14] Bacterial super-infection to lesions of CL is considered to be one of the complications of this disease which is incriminated to be the cause of the resistant cases to proven therapy. So that combating this super-infection is thought to be very helpful to reduce the possibility of resistance and better response to the treatment plan.[15] Macrolides especially azithromycin and clarithromycin had been studied to be effective against Leishmania species of old world, but these studies were not conducted on the lesions of human being.[16][18] Azithromycin due to its property of achieving high concentration in macrophages is promising in treatment of lesions of CL.[18][19] In Erbil governorate after the outbreak of CL we tried conduct this study to compare combination therapy of azithromycin and SSG intra-lesionally to SSG intra-lesionally alone as monotherapy.

PATIENTS AND METHODS

Prospective open labeled randomized controlled study conducted from September 2016 up to March 2017 in “Erbil Dermatology Teaching Center” in Erbil, Kurdistan, Iraq. Sixty three patients with cutaneous leishmaniasis were assigned to be included in this study. Patients were diagnosed clinically by two separate dermatologists and then confirmed parasitologically through detection of Donovan’s bodies in the smears taken from patients’ lesions. The study sample randomly divided into 2 groups; the patients randomized by block randomization method through possible balanced combinations with 2 patients to treatment group and the following 2 patients to control group. The first group A were 31 patients received intral-lesional (IL) sodium stibogluconate only, 0.5-1 ml per each lesion and the session repeated after 2 weeks, the second group B were 32 patients received intra-lesional sodium stibogluconate in the same dosage and frequency as in group A and oral azithromycin tablet 500mg three successive days per week for up to 2 months. Patients were controlled for the clinical improvement at two follow up points. First follow up point was 6th week from start of the treatment and the second control was at the end of 8th week of therapy (Figure-1). On both follow up point size of induration and photography of the lesions were
taken. Response scaled as complete healing, very good response, good response and poor response when there was reduction in the size of induration of lesions in 100%, 75%-99%, 25%-74% and less than 25% respectively. Statistical analysis of the data done by using the software SPSS program version 22.

Fig 1. Study flowchart according consort stands
RESULTS
Total 63 patients suffering from cutaneous leishmaniasis included in this study. Among them 49 were males and 14 were females. The age ranged between 7-64 years, the mean of 35 ± 10.4 years. There were no difference between mean ages of both group A and B (P > 0.05). (Table-1).

Table 1. Main characteristics of patients in both groups.

| Characteristic | Group a (SSG) N=31 | Group b (SSG + azithromycin) N = 32 |
|---------------|-------------------|-----------------------------------|
| Age / years*  | 32 ± 8.2          | 37 ± 7.4                          |
| Sex           | Male 23, Female 8 | Male 26, Female 6                 |
| Number of lesions* | 9 ± 2.3      | 8 ± 3.1                           |
| Duration of lesions / weeks* | 3 ± 1.1      | 2.4 ± 1.8                         |
| Size of lesions / mm*    | 3.1 ± 0.6      | 2.8 ± 0.4                         |

* P value > 0.05

Majority of the lesions in this sample were nodular (71.5%). Ulceration was dominant characteristic of the lesions found in 59% of the lesions (Table-2). The duration of the lesions at the time of presentation was ranged between 3 and 9 weeks, mean of 3 ± 1.1 and 2.4 ± 1.8 weeks in patients of group A and B respectively. The difference between both group number of lesions and their durations was not found (P > 0.05). (Table-1). Commonest site of lesions were foot, forearms, hands, face and legs, 23%, 20%, 17% and 15% respectively. (Figure-2).

Table 2. Type of cutaneous lesions and their ulceration

| Type of lesions | Number of lesions | Ulceration |
|----------------|------------------|------------|
|                |                  | Yes        | No         |
| Papule         | 17 (10.8%)       | 1 (5.8%)   | 16 (94.2%) |
| Patch          | 28 (17.7%)       | 25 (89.2%) | 3 (10.8%)  |
| Nodule         | 113 (71.5%)      | 68 (60.1%) | 45 (39.9%) |
| Total          | 158              | 94 (59.5%) | 64 (40.5%) |

Fig 2. Distribution of lesions over body anatomic areas
At 6th week follow up: in group A complete healing of the lesions was found in 13(41.9%) patients and very good response found in 8(25.8%) patients. In group B complete healing was found in 23(71.8%) patients and very good response was found in 6(18.7%). (Table-3). At the end of 8th week in group A complete healing of the lesions was increased and number of patients become 21(67.7%) patients while in patients of group B complete healing found in 27(84.3%). (Table-3).

| Follow up                              | 6th week | End of 8th week |
|----------------------------------------|----------|-----------------|
|                                        | Gr. A (N=31) | Gr. B (N=32) | Gr. A (N=31) | Gr. B (N=32)  |
| Poor Response                          | 7 (22.5%) | 2 (6.3%)       | 3 (9.7%)     | 0 (0%)        |
| Good response                          | 3 (9.8%)  | 1 (3.1%)       | 1 (3.2%)     | 2 (6.3%)      |
| Very good response                     | 8 (25.8) | 6 (18.7%)      | 6 (19.4%)    | 3 (9.4%)      |
| Complete healing                       | 13 (41.9)| 23 (71.8%)     | 21 (67.7%)   | 27 (84.3%)    |
| Total                                  | 31       | 32             | 31           | 32            |

During the course of therapy no significant side effects of drugs had been observed apart from pain during intra-lesional injections in all patients, gastric upset in 3 patients and dizziness in 1 patient in the patients group receiving azithromycin orally in combination to IL sodium stibogluconate, while in patients receiving only IL sodium stibogluconate no such adverse effects seen apart from pain during intra-lesional injections.

DISCUSSION

Cutaneous leishmaniasis it is the parasitic infection that have different treatment options but no one was found to have satisfactory for both clinician and patient, in which resistance to treatment is the main problem that face therapy introduction.[20,21] Sodium stibogluconate still is the treatment number one in management of CL in Iraq but emergence of difficult cases make to think about alternative ways of treatment.[20] In this study we tried to augment the effect of sodium stibogluconate by its combination with azithromycin orally. We observed that earlier resolution of the condition could be found in a very good proportion of the patients, at 6th week of therapy when IL sodium stibogluconate combined with oral azithromycin 71.8% of patients while in cases of monotherapy with IL sodium stibogluconate was only in 41.9% of the patients (P < 0.001). Azithromycin has antiprotozoal and antileishmanial effect,[16,17] Eglal and coauthors tried oral azithromycin in combination with multifosine for the treatment of Leishmania major infection in mice, they proved the effectiveness of this drug.[18] Secondary bacterial infection of CL lesions in some case could complicate course of the disease.[18,21] So that the synergistic effect of both azithromycin and sodium stibogluconate could be due to the antibacterial effect of azithromycin which can eliminate secondary bacterial infection of the lesions. In our study there were some cases that did not healed after 8 weeks therapy in patients receiving IL SSG (poor response 9.7% and good response 3.2%). This proportion could be due to strains that not respond to this treatment, as recently in some countries identification of species carried because drug and treatment plan is species directed.[22] We can conclude that further studies to be conducted to see the effect of these combination therapy on different species of CL in Iraq to identify the species which is sensitive to the suggest treatment. These need to provide identification of Leishmania species in all case
of CL before the introduction of therapy which will provide more cost and time effective therapy; also it will reduce probability of non-responding cases. According to the results of this study we conclude that oral azithromycin in combination with IL sodium stibogluconate can achieve earlier healing of the lesion and less possibility of resistant cases.

REFERENCES
1. Alsamarai AM, Alobaidi HS. Cutaneous Leishmaniasis in Iraq. J infect in develop count. 2009; 3: 123-129.
2. Alvar J, V élez ID, Bern C. Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS One. 2012; 7: 35671.
3. WHO. Country Cooperation Strategy for WHO and Iraq, 2012-2017. World Health Organization, Regional Office for the Eastern Mediterranean, WHO 2013; 1-52.
4. Abdulla QB. Factors associated with the outbreak of cutaneous leishmaniasis in Erbil governorate in 2015. KBMS dissertation. Kurdistan board for medical specialties. Iraq; 2017.
5. Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology. Third edition. Elsevier Limited. 2012: 1360-1378.
6. Goldsmith L, Katz S, Gilchrest B. Fitzpatrick's Dermatology in General Medicine, 8th edition. McGraw-Hill. 2008: 2001-2010.
7. Reedijk SH, Schallig HD. Cutaneous leishmaniasis: recent developments in diagnosis and management. 2015; 16:99-109.
8. Piscopo TV and Azzopardi CM. Leishmaniasis. Post-grad Med J. 2007. 83: 649-657
9. Bennis I, Severine T, Filali H, Brouwere VD, Shihabi H, Boelaert M. Psychosocial impact of scars due to cutaneous leishmaniasis on high school students in Erachidia province, Morocco. Infect Dis of Pover J. 2017; 6: 44-53.
10. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intraleisional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS ONE. 2017; 9: e0184777.
11. Salah AB, Messaoud NB, Guedri E. Topical Paromomycin for Cutaneous Leishmaniasis. N Eng J Med. 2013. 6: 524-532.
12. Khatami A, Firooz A, Gorouhi F, and Dowlati Y. Treatment of acute old world cutaneous leishmaniasis: A systematic review of the randomized controlled trials. J Am Acad Dermatol. 2007; 57: 335.e1-335.e29.
13. Arevalo I, Ward B, Miller R, Meng T. Successful treatment of drug-resistant cutaneous Leishmaniasis in humans by Use of Imiquimod, an Immunomodulator. Clini Infect Dis. 2001. 33:1847-1851.
14. Al-Natour SH. Update in the treatment of cutaneous leishmaniasis. J Family Comm Med. 2009; 16: 41–47.
15. Doudi M, Setorki M, Narimani M. Bacterial super infection in Zoonotic Cutaneous Leishmaniasis. Medical Science Monitor. 2012; 9: 356-361.
16. Prata A, Silva-Vergara ML, Costa L. Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical. 2003; 1:65-69
17. Sazgarnia A, Zabolinejad N, Layegh P, Rajabi O, Berenji F, Javidi Z, Salari R. Antileishmanial Activity of Liposomal Clarithromycin against Leishmania Major Promastigotes. Iranian Journal of Basic Medical Sciences. 2011; 6:1210-1214
18. Amer EI, Eissa MM, Mossallam SF. Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis. J Parasit Dis. 2016; 2: 475-484.
19. Oliveira-Silva F, Morais-Teixeira E, Rabello A. Antileishmanial Activity of Azithromycin Against Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi. Am. J. Trop. Med. Hyg. 2008; 5: 745-749
20. Control of the leishmaniases: WHO technical report series no. 949. Geneva: World Health Organization, 2010.
21. Simon L. Croft I, Sundar S, Fairlamb AH. Drug Resistance in Leishmaniasis. Clin. Microbiol. Rev. 2006; 1: 111-126.
22. Hodiamont CJ, Kager PA, Bart A. Species-Directed Therapy for Leishmaniasis in Returning Travellers: A Comprehensive Guide. PLoS neglected tropical diseases. 2014; 5: e2832.